Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
BM immune cell composition reflects myeloma progression and affects treatment response, with higher granulocyte-to-lymphocyte and granulocyte-to-T-lymphocyte ratios associated with improved PFS and outcomes with daratumumab therapy.”
Title: Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response
Authors: Anna Maria Corsale, Mojtaba Shekarkar Azgomi, Emilia Gigliotta, Marta Di Simone, Paola Pacelli, Francesca Cioffi, Elena Bestoso, Donatella Raspadori, Alessandro Gozzetti, Antonio Solimando, Paula Tabares, Andreas Beilhack, Maria Speciale, Giusy Corsale, Miriam Sciortino, Cristina Aquilina, Fulvio Brucato, Michele Cea, Renato Zambello, Francesca Garofano, Marta Biondo, Francesca Buffa, Nadia Caccamo, Francesco Dieli, Serena Meraviglia, Sergio Siragusa, and Cirino Botta.
You can read the Full Article in Blood Neoplasia.
You can find more posts featuring Robert Orlowski on OncoDaily.
